AI-Generated Filing Summaries

Ternium S.A. filed a Form 6-K furnishing notice of its Annual General Meeting of Shareholders on May 12, 2026, at 9:00 a.m. Luxembourg time, with agenda items including approval of 2025 consolidated financial statements and annual accounts, board discharge and election, director compensation, auditor appointment, and share repurchase authorization.

Ternium S.A. announced its Annual General Meeting of Shareholders to be held on May 12, 2026, at 9:00 a.m. CET at its registered office in Luxembourg. ADS holders as of March 30, 2026, are entitled to instruct The Bank of New York Mellon Corporation on voting rights.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, reported a net loss of $16.8 million for FY 2025, ending December 31, 2025, compared to $14.4 million in FY 2024, driven by increased operating expenses of $18.1 million versus $14.9 million prior year. Research and development expenses rose to $10.2 million from $9.1 million, reflecting higher clinical trial costs for PALI-2108 Phase 1 study and employee-related expenses, partially offset by reduced preclinical joint development costs. General and administrative expenses increased to $7.9 million from $5.8 million due to higher stock-based compensation and professional fees. Balance sheet strengthened significantly with cash and cash equivalents at $133.4 million, up from prior periods, fueled by $134.4 million net cash from financing activities, including $128.2 million from October 2025 common stock and warrants offering. Net cash used in operations was $10.8 million. Total assets reached $134.3 million, stockholders' equity $129.4 million. Forward-looking, the company plans Phase 2 trials for PALI-2108 in UC and CD in 2026, supported by strong liquidity positioning it for clinical advancement without near-term funding needs.

The Board of Trustees of Monroe Capital Enhanced Corporate Lending Fund declared a $0.20 per share dividend for Class I common shares, record date March 31, 2026, payable in cash on or about April 22, 2026. As of February 28, 2026, Class I Share NAV was $25.69, total NAV approximately $102.5 million, principal debt outstanding $112.0 million (debt-to-equity 1.09x), and portfolio investments in 38 companies at $209.6 million fair value.

Armada Acquisition Corp. III, a Cayman Islands-incorporated blank check company formed on September 19, 2025, reported a net loss of $53K for FY 2025 ended December 31, 2025, driven entirely by $53K in general and administrative costs, with no revenue as it conducted no substantive operations prior to its Initial Public Offering (IPO). Total assets stood at $332K, comprising $4K cash and $328K deferred offering costs. Liabilities totaled $360K, including $32K accrued expenses, $292K accrued offering costs, and $36K promissory note to related party, resulting in a shareholders' deficit of $28K. Net cash used in operating activities was $21K, with financing activities providing $25K net cash from Class B ordinary shares issuance and related party note, offset by deferred offering costs payments. Post-period, on February 19, 2026, the company completed its IPO raising $248.5M gross proceeds, placing $248.5M into trust, positioning it to pursue an initial business combination in FinTech, SaaS, or AI sectors within 18 months, with targets valued at least 80% of trust assets.

Banco Macro S.A. disclosed allocation of AR$290,438,875,537.79 retained earnings as of December 31, 2025: AR$57,898,528,529.31 to Legal Reserve Fund, AR$13,680,229,087.73 to Personal Asset Tax, and AR$218,860,117,920.75 to Optional Reserve Fund. It proposes releasing AR$300,000,000,000 from Optional Reserve for dividends at AR$469.1969827049 per share, subject to BCRA approval, to provide shareholder returns.

Ternium S.A. furnished its Annual Report for the year ended December 31, 2025, reporting net sales of $15,609 million, operating income of $705 million, and net income of $303 million. The report details steel shipments of 15,060 thousand tons, a proposed dividend of $2.70 per ADS, and $1.25 billion green financing for Pesquería expansion, providing investors with full-year financial and operational results.

argenx SE announced its Annual General Meeting of shareholders on May 6, 2026 at 13:00 CET at the Hilton Amsterdam Schiphol, with agenda items including adoption of 2025 annual accounts, advisory vote on 2025 remuneration report, director discharges, share issuance authorization, and proposed Board changes. These include appointments of Karen Massey as executive director and Tim Van Hauwermeiren as non-executive director for 4 years, re-appointments of Ana Céspedes, Camilla Sylvest for 4 years and Pamela Klein for 2 years, and retirement of Jim Daly effective May 6, 2026.

Scorpio Tankers Inc. announced the availability of its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC and accessible on the Company’s website in the Investor Center under Reports & Presentations. Shareholders may request a free hard copy, and the release details the Company’s fleet of 89 product tankers and pending sales and newbuildings.

Encore Capital Group, Inc. disclosed that director Ms. Wendy Hannam will not stand for re-election at the 2026 Annual Meeting of Stockholders, with no disagreements with the Company, and she will serve until the meeting. The Board approved amended and restated bylaws effective March 18, 2026, enhancing stockholder nomination disclosures, notice requirements, and meeting procedures to strengthen governance.

On March 18, 2026, Black Rock Coffee Bar, Inc. entered into an irrevocable proxy with the Jacob V. Spellmeyer 2021 Trust, Juliet A. Spellmeyer 2021 Trust, Bryan D. Pereboom 2021 Trust, and Nicole R. Pereboom 2021 Trust, Class C common shareholders, granting the Company, its Chief Executive Officer, or designees authority to vote their Covered Shares of Class A, Class B, or Class C common stock until the later of two years from that date or termination of the September 11, 2025 Voting Agreement.

Lightwave Logic, Inc. reported a net loss of $20.3 million for FY 2025, an improvement from $22.5 million in FY 2024, driven by reduced R&D expenses to $11.5 million from higher prior levels and lower prototype costs, partially offset by increased SG&A to $9.5 million. Net sales were $237K, primarily from licensing/royalty ($107K) and non-recurring engineering ($130K), with cost of revenue at $7K. Operating loss was $20.8M, mitigated by $842K interest income and $370K commitment fee. Balance sheet strengthened with cash and equivalents at $69.0M (up from $27.7M prior year), total assets $79.2M, and stockholders' equity $74.6M, fueled by $56.9M net financing cash inflows from stock issuances including $32.8M Titan offering and $18.8M ATM sales. Operating cash use was $13.7M, investing $1.8M. The company, with 34 employees and 67 patents, advances EO polymers for AI/data center photonics via material sales/IP licensing. Management anticipates 2026 revenues from materials/NRE, production ramp possibly 2027, with cash sufficient through 2027.

TG Therapeutics entered into the First Amendment to its Financing Agreement on March 18, 2026, establishing a $750 million 2026 Term Loan facility fully borrowed on the Closing Date to repay prior Initial Term Loans, and an uncommitted $250 million additional facility. The term loan matures on March 18, 2031, is secured by substantially all assets, and features interest based on SOFR or base rate plus applicable margin.

AutoZone, Inc. delivered robust revenue growth in its fiscal Q2 2026 10-Q filing for the twelve weeks ended February 14, 2026. Net sales increased 8% year-over-year to $4.27 billion from $3.95 billion, driven by higher sales volume in its single Auto Parts segment. Gross profit rose 5% to $2.24 billion, supported by sales expansion despite cost of sales at $2.03 billion. Operating profit dipped 1% to $698.5 million amid elevated operating, selling, general, and administrative expenses of $1.54 billion, up from $1.42 billion prior year. Income before taxes was $591.3 million, with net income at $468.9 million, down 4% YoY, yielding diluted EPS of $27.63 versus $28.29. For the twenty-four weeks, net sales grew 8% to $8.90 billion, net income $999.7 million. Balance sheet shows total assets $20.44 billion, up from $19.36 billion at fiscal year-end, with cash $285.5 million, inventories $7.48 billion, and long-term debt $8.91 billion. Operating cash flow for the half totaled $1.32 billion, funding $652 million capex and $742 million treasury stock purchases. Stockholders' deficit improved to -$2.91 billion. Investors note ongoing share repurchases with $1.4 billion remaining authorization and tariff uncertainties.

Aptiv PLC announced early results, upsizing to $1,371,000,000 maximum aggregate consideration, and pricing terms for its subsidiary's cash tender offer to purchase various Senior Notes. The offer is conditioned on the Spin-Off of the Electrical Distribution Systems business into Versigent and receipt of at least $1,700,000,000 special dividend, enabling potential debt reduction.

Star Equity Holdings, Inc. reported FY 2025 revenues of $172.2 million, up 23% YoY from $140.1 million in 2024, driven by the August 2025 acquisition of Star Operating Companies adding Building Solutions ($27.6M) and Energy Services ($4.9M) segments, offsetting a slight decline in Business Services from $140.1M to $139.7M. Gross profit rose 14% to $79.9M from $70.2M, with gross margin contracting to 46.4% from 50.1% due to higher costs in new segments. Operating loss narrowed slightly to -$3.7M from -$3.8M, but net loss widened to -$5.9M from -$4.8M, reflecting a $2.1M tax provision and $0.7M preferred dividends, yielding EPS of -$2.00 vs. -$1.59 prior year. Cash used in operations was -$7.3M, with net cash decrease of -$4.3M; total assets grew to $113.2M from $52.6M post-merger. The merger enhances diversification across building, business services, energy, and investments, positioning for organic growth and acquisitions amid competitive markets.

Star Equity Holdings, Inc. reported FY 2025 revenues of $172.2 million, up 23% YoY from $140.1 million in 2024, driven by the August 2025 acquisition of Star Operating Companies adding Building Solutions ($27.6M) and Energy Services ($4.9M) segments, offsetting a slight decline in Business Services from $140.1M to $139.7M. Gross profit rose 14% to $79.9M from $70.2M, with gross margin contracting to 46.4% from 50.1% due to higher costs in new segments. Operating loss narrowed slightly to -$3.7M from -$3.8M, but net loss widened to -$5.9M from -$4.8M, reflecting a $2.1M tax provision and $0.7M preferred dividends, yielding EPS of -$2.00 vs. -$1.59 prior year. Cash used in operations was -$7.3M, with net cash decrease of -$4.3M; total assets grew to $113.2M from $52.6M post-merger. The merger enhances diversification across building, business services, energy, and investments, positioning for organic growth and acquisitions amid competitive markets.

Morgan Stanley Bank of America Merrill Lynch Trust 2017-C34's 10-K filing for FY ended December 31, 2025, confirms full compliance with Regulation AB servicing criteria by all servicers, including master servicers Wells Fargo (until March 1, 2025) and Trimont thereafter, special servicers LNR Partners (until March 13, 2025) and Green Loan Services, and others like KeyBank. No XBRL financial statements are provided, as this is a CMBS trust focused on asset servicing rather than operational results. The pool comprises commercial mortgage loans, with key assets including American Cancer Society Center (9.5% of cut-off pool), 222 Second Street (9.5%), 237 Park Avenue (6.7%), OKC Outlets (4.7%), Mall of Louisiana (4.2%), and 9-19 9th Avenue (4.8%). No single obligor exceeds 10% of pool assets per Item 1112(b). Servicing transfers occurred: Trimont assumed master/primary roles March 1, 2025; Green Loan Services special servicer for 237 Park Avenue March 13, 2025. No material legal proceedings (Item 1117), no enhancements/derivatives (Items 1114/1115). Compliance assessments and attestations filed for all servicers. This underscores stable servicing amid transitions, vital for investor trust in CMBS performance.

For fiscal year 2025 ending December 31, 2025, the BDC generated total investment income of $2.15 billion, including $52.9 million in dividend income. Total expenses reached $1.03 billion, driven by interest expense of $678.8 million, management fees of $137.6 million, income-based incentive fees of $162.7 million, offset by a $12.9 million capital gains incentive fee credit, professional fees of $6.5 million, and other administrative costs. This yielded net investment income before excise tax of $1.12 billion, reduced slightly by $7.5 million excise tax, resulting in $1.12 billion after tax. Net realized losses totaled $159.1 million, including -$37.0 million on investments and -$122.3 million on foreign currency forward contracts. Net unrealized depreciation was $19.6 million, comprising $167.8 million gain on investments offset by foreign currency items. Overall, net increase in net assets resulting from operations was $938.6 million. Cash flows reflected heavy investment activity: operating activities used $8.07 billion net, due to $11.76 billion purchases versus $2.90 billion proceeds. Financing activities provided $8.43 billion, from $16.44 billion borrowings, $4.48 billion share issuances, offset by $11.09 billion repayments and $630.9 million distributions, yielding $361.8 million net cash increase. As of December 31, 2025, indebtedness stood at $12,989.7 million with a 5.96% weighted average rate; portfolio included 18.8% software and 12.5% healthcare at fair value. This underscores robust income amid leverage and portfolio activity, with liquidity supported by financing.

Standard Premium Finance Holdings, Inc. (SPFX) reported strong FY 2025 performance in its 10-K filing, with total revenues of $12.5M, up 2.7% YoY from $12.1M in 2024, driven by a 4.1% increase in finance charges to $11.0M (88% of revenue) amid 5.8% higher originations at $158.1M and 27,020 new loans. Net income rose 23.9% to $1.2M from $1.0M, boosted by lower interest expense (down 6.8% to $4.1M due to reduced rates and line of credit extension) despite higher commissions and salaries. Income before taxes increased 20.6% to $1.6M. Balance sheet grew to $74.8M in total assets, with premium finance contracts net at $72.8M (allowance $2.2M) and line of credit at $49.2M. Stockholders' equity stood at $8.5M. Operating cash flow was $2.9M, supporting investing outflows of $10.1M from $10.0M in new disbursements. Management highlights organic growth via state expansions (41 licenses), marketing hires, and $75M line of credit (to 2028), positioning for sustained profitability with ROA at 1.56% and ROE at 17.58%. Risks include credit losses and funding reliance.

On March 19, 2026, the Board of AN2 Therapeutics, Inc. approved a stock option repricing of all outstanding Eligible Options under the 2017 and 2022 Equity Incentive Plans to $3.91 per share, including options held by named executive officers and non-employee directors. This provides retention incentives without stock dilution or additional cash costs.

AA Mission Acquisition Corp. II (DNMX), a Cayman Islands blank check company formed on June 20, 2025, reported net income of $785K for FY 2025 ending December 31, 2025. As a SPAC with no operations or revenue, profitability stemmed from $1.3M in dividends earned on Trust Account investments, plus $4K interest on cash, offsetting $508K general and administrative costs and resulting in a $508K operating loss. The company completed its IPO on October 31, 2025, issuing 20,125,000 units at $10.00, generating $201.25M gross proceeds, of which $201.25M was placed in trust. At year-end, Trust investments stood at $202.5M (20,125,000 Class A shares at $10.06 redemption value), total assets at $203.9M, liabilities at $8.3M (including $8.1M deferred underwriting), and shareholders' deficit at -$6.8M. Cash outside trust was $1.3M. Net cash used in operations was -$382K, investing -$201.2M, financing +$203.0M. This is the inaugural period post-IPO; no prior year comparisons available. Forward-looking, the SPAC targets a business combination by October 31, 2027, focusing on energy, power, and digital infrastructure sectors with $1.0-$1.5B enterprise value targets, leveraging team expertise in AI-driven power demand.

AA Mission Acquisition Corp. II (DNMX), a Cayman Islands blank check company formed on June 20, 2025, reported net income of $785K for FY 2025 ending December 31, 2025. As a SPAC with no operations or revenue, profitability stemmed from $1.3M in dividends earned on Trust Account investments, plus $4K interest on cash, offsetting $508K general and administrative costs and resulting in a $508K operating loss. The company completed its IPO on October 31, 2025, issuing 20,125,000 units at $10.00, generating $201.25M gross proceeds, of which $201.25M was placed in trust. At year-end, Trust investments stood at $202.5M (20,125,000 Class A shares at $10.06 redemption value), total assets at $203.9M, liabilities at $8.3M (including $8.1M deferred underwriting), and shareholders' deficit at -$6.8M. Cash outside trust was $1.3M. Net cash used in operations was -$382K, investing -$201.2M, financing +$203.0M. This is the inaugural period post-IPO; no prior year comparisons available. Forward-looking, the SPAC targets a business combination by October 31, 2027, focusing on energy, power, and digital infrastructure sectors with $1.0-$1.5B enterprise value targets, leveraging team expertise in AI-driven power demand.

AA Mission Acquisition Corp. II (DNMX), a Cayman Islands blank check company formed on June 20, 2025, reported net income of $785K for FY 2025 ending December 31, 2025. As a SPAC with no operations or revenue, profitability stemmed from $1.3M in dividends earned on Trust Account investments, plus $4K interest on cash, offsetting $508K general and administrative costs and resulting in a $508K operating loss. The company completed its IPO on October 31, 2025, issuing 20,125,000 units at $10.00, generating $201.25M gross proceeds, of which $201.25M was placed in trust. At year-end, Trust investments stood at $202.5M (20,125,000 Class A shares at $10.06 redemption value), total assets at $203.9M, liabilities at $8.3M (including $8.1M deferred underwriting), and shareholders' deficit at -$6.8M. Cash outside trust was $1.3M. Net cash used in operations was -$382K, investing -$201.2M, financing +$203.0M. This is the inaugural period post-IPO; no prior year comparisons available. Forward-looking, the SPAC targets a business combination by October 31, 2027, focusing on energy, power, and digital infrastructure sectors with $1.0-$1.5B enterprise value targets, leveraging team expertise in AI-driven power demand.

AA Mission Acquisition Corp. II (DNMX), a Cayman Islands blank check company formed on June 20, 2025, reported net income of $785K for FY 2025 ending December 31, 2025. As a SPAC with no operations or revenue, profitability stemmed from $1.3M in dividends earned on Trust Account investments, plus $4K interest on cash, offsetting $508K general and administrative costs and resulting in a $508K operating loss. The company completed its IPO on October 31, 2025, issuing 20,125,000 units at $10.00, generating $201.25M gross proceeds, of which $201.25M was placed in trust. At year-end, Trust investments stood at $202.5M (20,125,000 Class A shares at $10.06 redemption value), total assets at $203.9M, liabilities at $8.3M (including $8.1M deferred underwriting), and shareholders' deficit at -$6.8M. Cash outside trust was $1.3M. Net cash used in operations was -$382K, investing -$201.2M, financing +$203.0M. This is the inaugural period post-IPO; no prior year comparisons available. Forward-looking, the SPAC targets a business combination by October 31, 2027, focusing on energy, power, and digital infrastructure sectors with $1.0-$1.5B enterprise value targets, leveraging team expertise in AI-driven power demand.

AA Mission Acquisition Corp. II (DNMX), a Cayman Islands blank check company formed on June 20, 2025, reported net income of $785K for FY 2025 ending December 31, 2025. As a SPAC with no operations or revenue, profitability stemmed from $1.3M in dividends earned on Trust Account investments, plus $4K interest on cash, offsetting $508K general and administrative costs and resulting in a $508K operating loss. The company completed its IPO on October 31, 2025, issuing 20,125,000 units at $10.00, generating $201.25M gross proceeds, of which $201.25M was placed in trust. At year-end, Trust investments stood at $202.5M (20,125,000 Class A shares at $10.06 redemption value), total assets at $203.9M, liabilities at $8.3M (including $8.1M deferred underwriting), and shareholders' deficit at -$6.8M. Cash outside trust was $1.3M. Net cash used in operations was -$382K, investing -$201.2M, financing +$203.0M. This is the inaugural period post-IPO; no prior year comparisons available. Forward-looking, the SPAC targets a business combination by October 31, 2027, focusing on energy, power, and digital infrastructure sectors with $1.0-$1.5B enterprise value targets, leveraging team expertise in AI-driven power demand.

U.S. GoldMining Inc., an exploration-stage company focused on the Whistler gold-copper project in Alaska, reported a net loss of $7.0 million for FY 2025, improved from $8.5 million in FY 2024, driven by lower exploration expenses of $3.0 million versus $5.8 million prior year, reflecting a shift to lower-cost scout auger drilling from diamond core drilling. Total operating expenses were $7.1 million, with general and administrative up to $3.9 million from $2.9 million due to higher stock-based compensation and investor relations. Loss from operations was $7.1 million. Balance sheet strengthened with cash and equivalents at $7.4 million (up from $3.9 million), total assets $8.4 million, and stockholders' equity $7.6 million. Net cash used in operations $5.8 million offset by $9.3 million financing from at-the-market equity sales. Post-year end, positive PEA for Whistler showed after-tax NPV5% of $2.04 billion, IRR 33%, highlighting development potential with 3.6 Moz AuEq production over 14.6 years at $1.28 billion initial capex. No revenue generated as pre-production. Liquidity supports 2026 exploration plans amid single-project risk.

Oncolytics Biotech Inc. consummated its continuance from Alberta to British Columbia on March 17, 2026 at 09:01 AM Pacific Time under Certificate of Continuation C1582211. The company adopted Notice of Articles and Articles, effective upon the certificate, modifying common shareholder rights to be governed by the British Columbia Business Corporations Act instead of Alberta law.

Creative Medical Technology Holdings, Inc. (CELZ) reported minimal revenue of $6K for FY2025 ending December 31, 2025, down 45% from $11K in FY2024, primarily due to decreased CaverStem sales amid strategic reevaluation. Gross profit was $4K, reflecting cost of revenues at $2K. Operating expenses rose to $6.1M, driven by $2.3M in R&D and $3.8M in SG&A, resulting in an operating loss of -$6.1M, wider than prior year. Net loss attributable to CMTH was -$6.0M or -$3 per share (basic/diluted, 2.4M weighted shares), compared to -$5.5M or -$3.71 prior year. Balance sheet strengthened with cash at $7.2M (up from implied prior), total assets $7.8M, and stockholders' equity $7.5M. Operating cash use was -$5.9M, offset by $7.2M financing inflows from warrant exercises, yielding $1.3M net cash increase. Management notes sufficient cash through at least March 2027 but anticipates future capital raises for clinical trials in Type 1 Diabetes (CELZ-201 CREATE-1) and back pain (CELZ-201 ADAPT), highlighting biotech development risks and low revenue base.

Columbia Sportswear Company entered into a new Credit Agreement on March 19, 2026, providing a $500 million unsecured revolving credit facility maturing March 19, 2031, for working capital and general corporate purposes, and terminated its prior Credit Agreement dated July 12, 2022, with no outstanding loans. This refinances liquidity with updated terms including a funded debt ratio covenant of 3.75 to 1.00.